Table 1. Summary of meningococcal strains used to test serum bactericidal activity.
| Strain Name | Secondary Strain Designation | Capsular Group | Country | Year | fHbp Protein ID* | 1/Serum Bactericidal GMT† | Clonal Complex, (ST) | PorA VR Type | Reference | |
| NOMV-KO | NOMV-fHbp | |||||||||
| Senegal1/99 | A1 | A | Senegal | 1999 | 5 | <10 | 281 | 5 (5) | P1.20,9 | [59] |
| BuFa6/07 | A2 | A | Burkina Faso | 2007 | 5 | 16 | 108 | 5 (2859) | P1.20,9 | [59] |
| E23/03 | A3 | A | Ethiopia | 2003 | 5 | <10 | <10 | 5 (7) | P1.20,9 | [59] |
| Z1275 | A4 | A | Niger | 1963 | 4 | <10 | 100 | 1 (1) | P1.5–2,10 | [60] |
| E2/88 | A5 | A | Ethiopia | 2003 | 5 | <10 | 346 | 5 (7) | P1.20,9 | [59] |
| Z2491 | A6 | A | Gambia | 1983 | 5 | <10 | 6861 | 4 (4) | P1.7,13–1 | [61] |
| Niger1/95 | A7 | A | Niger | 1995 | 5 | 31 | 463 | 5 (5) | P1.20,9 | [59] |
| Niga3/07 | A8 | A | Nigeria | 2007 | 5 | <10 | 178 | 5 (7) | P1.20,9 | [59] |
| C50/01 | A9 | A | Congo | 2001 | 5 | <10 | <10 | 5 (7) | P1.20,9 | [42] |
| LNP20868 | A10 | A | Burkina Faso | 2003 | 5 | <10 | 306 | 5 (2859) | P1.20,9 | [59] |
| LNP20790 | A11 | A | Burkina Faso | 2003 | 5 | <10 | 71 | 5 (2859) | P1.20,9 | [59] |
| Nigeria4/03 | A12 | A | Nigeria | 2003 | 5 | 632 | 1643 | 5 (7) | P1.20,9 | [42] |
| Sudan11/07 | A13 | A | Sudan | 2007 | 5 | <10 | 109 | 5 (7) | P1.20,9 | [42] |
| BuFa20030378 | A14 | A | Burkina Faso | 2007 | 5 | <10 | 160 | 5 (6035) | P1.20,9 | [42] |
| Chad5/07 | A15 | A | Chad | 2007 | 5 | <10 | 183 | 5 (7) | P1.20,9 | [42] |
| H44/76 | B1 | B | Norway | 1976 | 1 | <10 | 736 | 32 (32) | P1.7,16 | [42] |
| SK140 | B2 | B | US | 2005 | 4 | <10 | 1151 | 41/44 (5097) | P1.7–2,4 | [42] |
| MD01327 | B3 | B | US | 1999 | 4 | <10 | 893 | 41/44 (2973) | P1.18,25 | [42] |
| NZ98/254 | B4 | B | New Zealand | 1998 | 14 | <10 | 368 | 41/44 (42) | P1.7–2,4 | [42] |
| M01573 | B5 | B | US | NA | 55 | <10 | 125 | 41/44 (44) | P1.7–1,1 | [22] |
| 675 | B6 | B | The Gambia | 1995 | 347 | <10 | 3065 | 41/44 (8233) | P1.7–1,1 | [42] |
| ††Su1/06 | W1 | W | Sudan | 2006 | 9 | 23280 | 25411 | 11 (11) | P1.5,2 | [59] |
| BuFa2-03 | W2 | W | Burkina Faso | 2003 | 23** | 2014 | 1243 | 11 (11) | P1.5,2 | [59] |
| Nigeria1/04 | W3 | W | Nigeria | 2004 | 22** | 87 | 34 | 175 (2881) | P1.5–1,2–36 | [42] |
| C6/01 | W4 | W | Congo | 2001 | 350 | 221 | 1753 | 175 (175) | P1.5–1,2–2 | [42] |
| BF 17/01 | W5 | W | Burkina Faso | 2001 | 9 | 1374 | 1294 | 11 (11) | P1.5,2 | [42] |
| Uganda12/06 | W6 | W | Uganda | 2006 | 349 | 1533 | 781 | 11 (11) | P1.5,2 | [42] |
| Mali1/06 | W7 | W | Mali | 2006 | 23** | 1309 | 753 | 11 (11) | P1.5,2 | [42] |
| BF 12/03 | X1 | X | Burkina Faso | 2003 | 73 | 38 | 1627 | 181 (751) | P1.5–1,10–1 | [42] |
| Kenya1/06 | X2 | X | Kenya | 2006 | 74 | <10 | 310 | UA (5403) | P1.19,26 | [42] |
| Uganda 23/06 | X3 | X | Uganda | 2006 | 74 | <10 | 277 | UA (5403) | P1.19,26 | [42] |
| Uganda 3/06 | X4 | X | Uganda | 2006 | 74 | <10 | 112 | UA (5403) | P1.19,26 | [42] |
| Uganda14/06 | X5 | X | Uganda | 2006 | 74 | <10 | 118 | UA (5403) | P1.19,26–4 | [42] |
| BF 5/97 | X6 | X | Burkina Faso | 1997 | 73 | <10 | 239 | 181 (751) | P1.5–1,10–1 | [42] |
| BuFa2-97 | X7 | X | Burkina Faso | 1997 | 73 | <10 | 446 | 181 (751) | P1.5–1,10–1 | [59] |
| BuFa7/07 | X8 | X | Burkina Faso | 2007 | 74 | 93 | 279 | 181 (181) | P1.5–1,10–1 | [59] |
| HF24 | X9 | X | S. Africa | 1970s | 4 | 21 | 160 | 181 (3687) | P1.7,9 | [42] |
| HF78 | X10 | X | S. Africa | 1970s | 4 | 11 | 359 | 181 (3687) | P1.7,9 | [42] |
As designated on the public website at http://pubmlst.org/neisseria/fHbp/. **fHbp sequence variant in group 2 (sub-family A); all other fHbp sequence variants are in group 1 (sub-family B) as designated on the public website.
For strains A01–A05, W01–W04, X01–X03, and B01–B05, the reciprocal GMT was calculated from titers of three serum pools (four animal each). These are shown graphically along with GMT of negative control mice immunized with aluminum hydroxide alone in Figure 5. For the remaining strains shown in Table 1, the reciprocal GMT was calculated from titers of two serum pools.
Strain used for construction of the vaccine strain.
In this publication we made use of the Neisseria Multi Locus Sequence Typing website (http://pubmlst.org/neisseria/) developed by Keith Jolley and sited at the University of Oxford [93], [94].